Free Speech

Showing 685 articles
Business

Amprius Technologies: Battery Innovator or Overheated Stock?

Amprius Technologies' shares have skyrocketed over 300% in the past year, driven by excitement around its silicon-anode battery technology. However, a deep dive into the company's financials reveals a significant valuation gap, raising questions about whether the stock's momentum has outpaced its fundamentals.

Business

AbCellera Biologics: A Tale of Two Valuations Amid Steep Share Decline

Shares of antibody discovery firm AbCellera Biologics plunged 16.8% last week, reigniting debate over its true worth. While a discounted cash flow model suggests deep undervaluation, its sky-high price-to-sales ratio paints a starkly different picture, leaving investors to navigate conflicting signals in a volatile biotech market.

Business

Dynatrace Stock Plunge: A Buying Opportunity or a Value Trap?

Dynatrace shares have tumbled over 34% in the past year, significantly underperforming the broader software sector. A deep dive into valuation metrics, including discounted cash flow and peer comparisons, suggests the stock may be trading at a substantial discount. We examine the numbers and the narrative shaping investor sentiment.

Business

New Gold Shareholders Overwhelmingly Approve Coeur Mining Acquisition, Paving Way for Major North American Precious Metals Player

Shareholders of New Gold Inc. (TSX:NGD) and Coeur Mining, Inc. have given resounding approval to Coeur's plan to acquire all outstanding shares of New Gold. The vote clears a critical path for the merger, which now awaits final regulatory and court nods to create a significantly larger, diversified precious metals producer with enhanced scale and exploration prospects across North America.